Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 25

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 25
---
 the Series A Warrant
Shares, the “Series Warrant Shares”), in each case, at an exercise price of $0.48 per share.

A total of (i) 40,000,000
Series A Warrants exercisable for an aggregate of approximately 81,911,262.80 shares of common stock (assuming the full exercise of the
Series A Warrants at an exercise price equal to the floor price of $0.0586), and (ii) 40,000,000 Series B Warrants exercisable for an
aggregate of approximately 982,935,153.58 shares of common stock (assuming (x) the full exercise of the Series B Warrants at an exercise
price equal to the floor price of $0.0586 and (y) all the Series B Warrants are exercised on the “zero exercise price” basis),
were issued in the Offering. Accordingly, an aggregate of approximately 1,064,846,416.38 additional shares of Common Stock will be outstanding
as a result of the full exercise of the Series Warrants and the ownership interest of our existing stockholders would be correspondingly
reduced

The securities offered in
the Offering were offered pursuant to a registration statement on Form S-1 (File No. 333-284495), as amended, originally filed
on January 24, 2025, and declared effective by the U.S. Securities and Exchange Commission on February 14, 2025, and an additional
registration statement on Form S-1 (No. 333-285005) filed on February 14, 2025, pursuant to Rule 462(b) as promulgated
under the Securities Act of 1933, as amended. The Offering closed on February 19, 2025, and the aggregate gross proceeds from the
Offering were approximately $9.6 million before deducting estimated offering expenses payable by the Company.

Series A Warrants

The following summary of certain terms and provisions of the Series A Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the Series A Warrant, the form of which was filed as an exhibit to the Current Report on Form 8-K filed by the Company on February 21, 2025. Our security holders entitled to vote on the Issuance Proposal should carefully review the terms and provisions of the form of Series A Warrant for a complete description of the terms and conditions of the Series